RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of Impax Laboratories (NASDAQ: IPXL) after WSJ reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE